Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance
作者:Yinhu Wang、Rumana Mowla、Liwei Guo、Abiodun D. Ogunniyi、Taufiq Rahman、Miguel A. De Barros Lopes、Shutao Ma、Henrietta Venter
DOI:10.1016/j.bmcl.2017.01.042
日期:2017.2
organisms. The compounds were tested for their antibacterial action, ability to potentiate the action of antibiotics and for their ability to inhibit Nile Red efflux by AcrB. None of the compounds were antimicrobial against E. coli wild type cells. Most of the compounds were able to inhibit Nile Red efflux indicating that they are substrates of the AcrB efflux pump. Three compounds were able to synergise
排毒泵使多种药物对危险的病原体具有抵抗力,这使这些泵成为重要的药物靶标。我们已经合成了一系列基于2-萘酰胺pharmacore的新型化合物,旨在抑制革兰氏阴性细菌的外排泵。大肠杆菌的弧形转运蛋白AcrB被用作模型外排泵,因为AcrB在整个革兰氏阴性生物中均被广泛保存。测试了这些化合物的抗菌作用,增强抗生素作用的能力以及它们通过AcrB抑制尼罗河红流出的能力。这些化合物均未对大肠杆菌产生抗药性野生型细胞。大多数化合物能够抑制尼罗红外排,表明它们是AcrB外排泵的底物。三种化合物能够与抗生素协同作用,并在耐药表型中逆转耐药性。化合物A3 4-(异戊氧基)-2-萘甲酰胺将红霉素和氯霉素的MIC降低到缺少外排泵的药物敏感菌株的MIC水平。A3对非底物利福平的MIC无影响,表明该化合物通过AcrB外排泵特异性发挥作用。A3也不通过非特异性机制如外膜或内膜透化起作用,并且对哺乳动物细胞系没有细胞毒性。所以,